Source BioScience technology to be used in NHS cancer screening

Source BioScience has announced that its BD FocalPoint 'No Further Review' technology is to be utilised in cervical cancer screening in the UK.

NHS Cancer Screening Programmes (NHSCSP) has approved the system following recommendations from the Health Technology Assessment Mavaric trial, which underlined the efficacy of its performance.

The BD FocalPoint system is able to analyse and identify up to a quarter of screening samples that can be reported as all clear without the need for human examination, which could offer numerous efficiency benefits for the UK health service.

It is the only automated cervical screening technology of its kind to be approved for NHS use.

Dr Nick Ash, chief executive of Source BioScience, said: "We believe BD FocalPoint is a huge step forward for cervical cancer screening progression in the UK."

Last month, the company announced that it will be working with life science firm Illumina and the Barts Cancer Institute to develop a new diagnostic test for use in personalised cancer treatments.